Allarity Therapeutics A/S

Allarity Therapeutics is a biotechnology firm that specializes on cancer precision medicine. Allarity Therapeutics, formerly known as Medical Prognosis Institute A/S, was created in 2004 and has since grown to focus on medication discovery and precision medicine for cancer.

To develop tailored cancer treatments, the business use its Drug Response Predictor (DRP) technology. The DRP technology analyzes a patient's own cancer cells to decide which cancer treatments are most likely to work for that person.

Allarity Therapeutics' pipeline includes three priority programs: stenoparib, 2X-121, and dovitinib. These projects are in various phases of clinical development and target various forms of cancer.

After undergoing a reorganization that turned the company from a Danish entity listed in Sweden to a US corporation listed on the NASDAQ stock exchange, Allarity Therapeutics was listed on the NASDAQ stock exchange in the United States in 2021.

Steve Carchedi, the company's CEO, joined the company in 2019. Several experienced professionals with backgrounds in biotech and pharmaceuticals fill out the leadership team.

Adgero Biopharmaceuticals and Sorrento Therapeutics are among the pharmaceutical businesses with which Allarity Therapeutics has collaborations. In order to further its research and development efforts, the corporation regularly interacts with academic organizations.

The company's goal is to create targeted cancer therapies that can enhance cancer patients' prognoses. Allarity Therapeutics seeks to deliver more effective and tailored cancer medicines with its DRP technology and individualized approach to cancer therapy.

Founded: 2004

Headquarters: Venlighedsvej 1, Hørsholm, DK

Website: https://allarity.com/